JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Home・Akciju saraksts・Pulmatrix Inc

Pulmatrix Inc

Slēgts

2.57 1.58

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.45

Max

2.59

Galvenie mērījumi
By Trading Economics
Ienākumi	672K -877K
EPS	-0.24
Peļņas marža	-60,266.667
Darbinieki	2
EBITDA	671K -877K

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-8.6M 9.3M
Iepriekšējā atvēršanas cena	0.99
Iepriekšējā slēgšanas cena	2.57

Pulmatrix Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 2. febr. 23:52 UTC

Iegādes, apvienošanās, pārņemšana

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2026. g. 2. febr. 23:52 UTC

Iegādes, apvienošanās, pārņemšana

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2026. g. 2. febr. 23:48 UTC

Tirgus saruna

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2026. g. 2. febr. 23:38 UTC

Tirgus saruna

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2026. g. 2. febr. 23:28 UTC

Tirgus saruna

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2026. g. 2. febr. 23:23 UTC

Peļņas

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2026. g. 2. febr. 22:57 UTC

Peļņas

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026. g. 2. febr. 22:22 UTC

Iegādes, apvienošanās, pārņemšana

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2026. g. 2. febr. 22:08 UTC

Tirgus saruna

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2026. g. 2. febr. 21:51 UTC

Peļņas

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026. g. 2. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 2. febr. 21:49 UTC

Peļņas

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2026. g. 2. febr. 21:39 UTC

Peļņas

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026. g. 2. febr. 21:36 UTC

Peļņas

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2026. g. 2. febr. 21:34 UTC

Peļņas

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026. g. 2. febr. 21:28 UTC

Iegādes, apvienošanās, pārņemšana

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2026. g. 2. febr. 21:23 UTC

Peļņas

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2026. g. 2. febr. 21:19 UTC

Peļņas

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2026. g. 2. febr. 21:17 UTC

Peļņas

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2026. g. 2. febr. 21:17 UTC

Peļņas

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026. g. 2. febr. 21:10 UTC

Peļņas

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026. g. 2. febr. 21:08 UTC

Peļņas

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2026. g. 2. febr. 21:07 UTC

Peļņas

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2026. g. 2. febr. 21:05 UTC

Peļņas

Palantir Technologies 4Q Net $608.7M >PLTR

2026. g. 2. febr. 21:05 UTC

Peļņas

Palantir Technologies 4Q Rev $1.41B >PLTR

2026. g. 2. febr. 21:05 UTC

Peļņas

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2026. g. 2. febr. 21:05 UTC

Peļņas

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2026. g. 2. febr. 21:05 UTC

Peļņas

Palantir Technologies 4Q Adj EPS 25c >PLTR

2026. g. 2. febr. 21:05 UTC

Peļņas

Palantir Technologies 4Q EPS 24c >PLTR

2026. g. 2. febr. 20:40 UTC

Tirgus saruna

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Salīdzinājums

Cenas izmaiņa

Pulmatrix Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Pulmatrix Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.